Evolution of the Average Target: Cartesian Therapeutics, Inc.

Evolution of the Target Price: Cartesian Therapeutics, Inc.

Changes in Analyst Recommendations: Cartesian Therapeutics, Inc.

62005e95ff799.jAwmok7yymYnuU0pPzahnUlxOBocdXEmFIdODBnaIXI.7T91jxafiQhEgT9hDBvtxzlBCFktOUgRIu0CVm-sRyrIZHbDJZCbCBX7FA~1ddb1407c94e36734cea4df637eb31c6
25-10-21 Cartesian Therapeutics, Inc. Announces Departure of Chief Scientific Officer, Christopher Jewell, Ph.D., Effective November 14, 2025 CI
25-07-09 Wedbush Initiates Cartesian Therapeutics at Outperform With $38 Price Target MT
24-12-19 BTIG Research Initiates Coverage on Cartesian Therapeutics With Buy Rating, $42 Price Target MT
24-08-06 TD Cowen Starts Cartesian Therapeutics With Buy Rating MT
24-07-03 Canaccord Genuity Raises Price Target on Cartesian Therapeutics to $43 From $38, Maintains Buy Rating MT
24-07-03 HC Wainwright Adjusts Price Target on Cartesian Therapeutics to $49 From $54, Maintains Buy Rating MT
24-07-02 Oppenheimer Downgrades Cartesian Therapeutics to Market Perform From Outperform; Shares Tumble MT
24-06-04 Oppenheimer Initiates Cartesian Therapeutics With Outperform Rating, $50 Price Target MT
24-05-24 Mizuho Securities Starts Cartesian Therapeutics With Buy Rating MT
24-04-23 Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
23-08-18 Mizuho Trims Price Target on Selecta Biosciences to $3 From $4, Maintains Buy Rating MT
23-08-18 Needham Adjusts Price Target on Selecta Biosciences to $4 From $5, Maintains Buy Rating MT
23-03-22 HC Wainwright Adjusts Price Target on Selecta Biosciences to $5 From $4, Maintains Buy Rating MT
23-03-22 Mizuho Securities Adjusts Selecta Biosciences Price Target to $4 From $5, Maintains Buy Rating MT
23-01-31 Canaccord Genuity Adjusts Selecta Biosciences Price Target to $9 From $10, Maintains Buy Rating MT
22-06-21 HC Wainwright Adjusts Price Target on Selecta Biosciences to $4 From $6, Reiterates Buy Rating MT
22-06-14 Needham Adjusts Price Target on Selecta Biosciences to $5 From $6, Reiterates Buy Rating MT
22-06-06 SVB Securities Initiates Selecta Biosciences at Outperform With $7 Price Target MT
21-06-15 Selecta Biosciences : BTIG Starts Selecta Biosciences at Buy With $10 Price Target MT
21-03-12 Selecta Biosciences : William Blair Upgrades Selecta Biosciences to Outperform from Market Perform MT
21-01-26 Selecta Biosciences : Mizuho Upgrades Selecta Biosciences to Buy From Neutral, Adjusts Price Target to $8 From $2.50 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+294.65%
+9.67%
+17.12%
+48.46%
+2.01%
+29.88%
+20.68%
-19.3%
+7.31%
-0.04%
Average +41.04%
Weighted average by Cap. +15.12%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
8.760USD
Average target price
34.57USD
Spread / Average Target
+294.65%
High Price Target
44.00USD
Spread / Highest target
+402.28%
Low Price Target
16.00USD
Spread / Lowest Target
+82.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Wedbush
BTIG
Oppenheimer
Mizuho Securities
Leerink Partners
Needham & Co.
HC Wainwright
Canaccord Genuity
SVB Securities LLC
William Blair & Co.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
8.760USD
Average target price
34.57USD
Spread / Average Target
+294.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RNAC Stock
  4. Consensus Cartesian Therapeutics, Inc.